H.R. 7407: Prohibiting Tianeptine and Other Dangerous Products Act of 2026

This bill, known as the Prohibiting Tianeptine and Other Dangerous Products Act of 2026, aims to amend the Federal Food, Drug, and Cosmetic Act to introduce new regulations concerning dietary supplements.

Key Provisions of the Bill

• Definition of Dietary Supplements: The bill expands on what constitutes a dietary supplement and prohibits the introduction or delivery of any product marketed as such if it does not meet this definition as specified in section 201 of the Act.
• Debarred Individuals: It prohibits the introduction or delivery of dietary supplements that have been prepared, packed, or held under the guidance of individuals who have been debarred under section 306 of the Act. This is aimed at ensuring that only reliable and compliant entities are involved in the dietary supplement market.
• Import Exclusions: The bill modifies the current rules regarding imports of dietary supplements by amending the stipulations in section 801(a) of the Act. It updates the law to reflect the new prohibited acts and related sections, thereby reinforcing the import restrictions on certain dietary products.
• Authority to Seize Products: The legislation grants additional seizure authorities to ensure compliance. It empowers federal officials to seize products that are deemed to be in violation of the new regulations outlined in the bill concerning dietary supplements.

Enforcement Mechanisms

The bill includes updated enforcement mechanisms that allow government agencies to better regulate the market for dietary supplements. This includes the ability to:

• Seize products that are imported in violation of the new guidelines.
• Take actions against companies that disregard the newly defined restrictions and prohibitions.

Impact on Public Health and Safety

The overall intention behind this legislation is to enhance public health and safety by preventing the distribution of potentially dangerous dietary supplements, including specific restrictions on substances like tianeptine, which is associated with various health risks.

The bill has been introduced in the House of Representatives and referred to the Committee on Energy and Commerce for further deliberation.

Relevant Companies

• None found